Paolo Abada

3.8k citations
63 papers · 2.3k indexed · 3 hit papers · h-index 19
Topics
Hepatocellular Carcinoma Treatment and Prognosis (33 papers)Pancreatic and Hepatic Oncology Research (17 papers)Chronic Lymphocytic Leukemia Research (12 papers)

In The Last Decade

Paolo Abada

60 papers receiving 2.3k citations

Hit Papers

Ramucirumab versus placebo as second-line treatment in pa...2015202620182022201520182019200400600

Peers

Paolo Abada
Comparison fields: 5 of 95
  • Hepatology 1.2k
  • Oncology 652
  • Molecular Biology 602
  • Cancer Research 538
  • Epidemiology 508
Replace Kazutaka Kurokohchi with:
Kazutaka Kurokohchi Japan
Chia-Jui Yen Taiwan
Thomas Decaens France
Bazarragchaa Damdinsuren Japan
Johann von Felden Germany
Józefa Węsierska‐Gądek Austria
Armand de Gramont France
Makoto Chuma Japan
Sachiko Ogasawara Japan
Hirofumi Akita Japan
Paolo Abada relative to Kazutaka Kurokohchi Japan Kazutaka Kurokohchi's profile →
Citations per field
00.5×10×15.0×
Kazutaka Kurokohchi · 1×
Citations per year

Countries citing papers authored by Paolo Abada

Since Specialization
Citations

This map shows the geographic impact of Paolo Abada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paolo Abada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paolo Abada more than expected).

Fields of papers citing papers by Paolo Abada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paolo Abada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paolo Abada. The network helps show where Paolo Abada may publish in the future.

Co-authorship network of co-authors of Paolo Abada

This figure shows the co-authorship network connecting the top 25 collaborators of Paolo Abada. A scholar is included among the top collaborators of Paolo Abada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paolo Abada. Paolo Abada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 2
2 2
3 3
4 1
5 1
6 9
7 56
8 13
9 18
10 1
11 9
12 21
13 1
14 27
15 1
16 1
17
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialbreakdown →
634
18 14
19 41
20 50

About Paolo Abada

Paolo Abada is a scholar working on Hepatology, Genetics and Cancer Research, having authored 63 papers that have together received 2.3k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (33 papers), Pancreatic and Hepatic Oncology Research (17 papers) and Chronic Lymphocytic Leukemia Research (12 papers). The work is most often cited by research in Hepatology (1.2k citations), Cancer Research (538 citations) and Pathology and Forensic Medicine (494 citations). Paolo Abada has collaborated with scholars based in United States, Japan and Germany. Frequent co-authors include Masatoshi Kudo, Andrew X. Zhu, Richard S. Finn, Weijing Sun, Richard D. Kim, Michael A. Morse, Aiwu Ruth He, Stephen B. Howell, Josep M. Llovet and Peter R. Galle. Their work appears in journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026